Related Experiment Video
Updated: May 26, 2026

Evaluation of Keratinocyte Proliferation on Two- and Three-dimensional Type I Collagen Substrates
Published on: April 22, 2019
Celecoxib suppresses fibroblast proliferation and collagen expression by inhibiting ERK1/2 and SMAD2/3
Fengfeng Li1, Cunyi Fan, Bingfang Zeng
1Department of Orthopaedics, The Sixth Affiliated People's Hospital, Shanghai Jiaotong University, Shanghai 200233, PR China.
Abstract:
This study aimed to investigate whether celecoxib suppresses fibroblast proliferation and collagen expression by inhibiting extracellular signal-regulated kinase 1/2 (ERK1/2) and SMAD2/3 phosphorylation. Celecoxib was added to NIH/3T3 fibroblasts stimulated by fibroblast growth factor-2 (FGF-2) or transforming growth factor-β1 (TGF‑β1). NIH/3T3 fibroblast proliferation and viability were assessed by MTT assays; ERK1/2 expression and SMAD2/3 expression were assessed by quantitative RT-PCR and Western blot analysis. The results indicated that celecoxib suppressed cell proliferation (IC50 FGF+ group, 75 ± 1.9 µmol/l) stimulated by FGF-2, and also inhibited cell viability (IC50 FGF- group, 252 ± 2.3 µmol/l) by inhibiting ERK1/2 phosphorylation but not ERK1/2 expression. In addition, celecoxib treatment led to the apoptosis of NIH/3T3 fibroblasts (IC50 FGF- group, 35 ± 1.4 µmol/l). Celecoxib also suppressed collagen expression (0.35-fold COL3 and 0.43-fold COL1 with 320 µmol/l celecoxib relative to the untreated group following stimulation for 3 h, p<0.01) when stimulated by TGF‑β1, by inhibiting SMAD2/3 phosphorylation but not SMAD2/3 expression. Celecoxib is capable of inhibiting ERK1/2 and SMAD2/3 phosphorylation, which is responsible for NIH/3T3 fibroblast proliferation and collagen expression.
Insights
Celecoxib inhibits fibroblast proliferation and collagen production by blocking key signaling pathways. This study demonstrates celecoxib
Area of Science:
- Cell Biology
- Pharmacology
Background:
- Fibroblast proliferation and collagen expression are critical in wound healing and fibrosis.
- Extracellular signal-regulated kinase 1/2 (ERK1/2) and SMAD2/3 pathways regulate these processes.
- Understanding how drugs modulate these pathways is crucial for therapeutic development.
Purpose of the Study:
- To investigate the effects of celecoxib on fibroblast proliferation and collagen expression.
- To determine if celecoxib inhibits these processes by modulating ERK1/2 and SMAD2/3 phosphorylation.
Main Methods:
- NIH/3T3 fibroblasts were stimulated with fibroblast growth factor-2 (FGF-2) or transforming growth factor-β1 (TGF‑β1).
- Celecoxib's effects on cell proliferation, viability, and apoptosis were assessed using MTT assays.
- Quantitative RT-PCR and Western blot analysis were used to measure ERK1/2 and SMAD2/3 expression and phosphorylation.
Main Results:
- Celecoxib suppressed FGF-2-stimulated fibroblast proliferation and viability.
- Celecoxib induced apoptosis in NIH/3T3 fibroblasts.
- Celecoxib inhibited TGF‑β1-stimulated collagen expression by reducing SMAD2/3 phosphorylation.
- Celecoxib inhibited ERK1/2 phosphorylation, impacting fibroblast proliferation.
Conclusions:
- Celecoxib effectively suppresses fibroblast proliferation and collagen expression.
- The mechanism involves the inhibition of ERK1/2 and SMAD2/3 phosphorylation.
- These findings suggest potential therapeutic applications for celecoxib in conditions involving excessive fibroblast activity.
Related Concept Videos
TGF - β Signaling Pathway
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
The JAK-STAT Signaling Pathway
Inhibition of Cdk Activity
Inhibition of CDK Activity
Fibril-associated Collagen
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
